ReviewCancer biology & medicine2026
Click chemistry-driven tumor theranostics: recent advances, challenges, and future perspectives.
Review in Cancer biology & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Tumor theranostics, which integrates accurate diagnosis and precise therapy, has emerged as a pivotal approach in modern oncology for improving treatment efficacy and reducing off-target toxicity. Click chemistry, which is characterized by high efficiency, selectivity, biocompatibility, and modularity, has become an indispensable tool for constructing versatile theranostic systems. This review systematically summarizes the recent progress in click chemistry-based tumor theranostic systems, starting with an overview of core click reactions and the unique features in biomedical applications. We then focus on the application of click chemistry within a diagnosis-therapy-theranostics framework to three key aspects of tumor theranostics: (i) tumor diagnosis (molecular imaging probes and circulating tumor cell detection); (ii) tumor therapy (chemotherapy, phototherapy, immunotherapy, and gene therapy); and (iii) integrated theranostics (multimodal imaging-guided combinatorial therapy). Furthermore, the current challenges, such as the biocompatibility of catalysts and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.